NORML
SEPTEMBER 20, 2019
Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials. Can you explain how it’s prepared for shipping at the University of Mississippi and how it comes packaged?
The Cannigma
FEBRUARY 11, 2021
Listen & Subscribe: When Mara Gordon started using medical cannabis there wasn’t any lab testing — or any way to know how much of each cannabinoid or terpene was in a given strain. All of that data is packaged into software doctors can use to manage their patients’ medical marijuana treatment. “I I know how to collect data.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 29, 2019
Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.
The Cannigma
DECEMBER 22, 2021
I do want to say that when it comes to anxiety, sleep, I mean, what we do, for example, in Bazelet, which is quite unique, as far as oil products are concerned, this is something that is we have a lot of intellectual property on the use of terpenes in creating cannabis formulations. We have, I think, eight PhDs.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).
Expert insights. Personalized for you.
231 
Let's personalize your content